Characteristics and outcomes of cases of children and adolescents with 1

pediatric inflammatory multisystem syndrome in a tertiary care center 2

- in Mexico City 3
- Ricardo Gil Guevara¹[†], María de Lourdes Marroquín Yáñez²[†], Rodolfo Norberto Jiménez-4
- Juárez^{3,4}, Víctor Olivar Lopez¹, Adrián Chávez Lopez², Juan José Luis Sienra Monge⁵, 5
- Lourdes Maria del Carmen Jamaica Balderas⁶, Silvia Alexandra Martínez Herrera¹, Clemen 6
- 7
- Domínguez-Barrera³, Julio Erdmenger Orellana⁷, Horacio Márquez González⁸, Miguel Klünder-Klünder⁹, Jaime Nieto Zermeño¹⁰, Mónica Villa Guillen¹⁰, Nadia González García¹¹*, 8
- Maria F Castilla-Peon¹² * 9
- [†]These authors have contributed equally to this work and share first authorship 10
- *These authors have contributed equally to this work and are both corresponding authors 11
- 12
- ¹ Emergency Medicine Department, Hospital Infantil de Mexico Federico Gomez Instituto Nacional 13
- de Salud, Mexico City, Mexico 14
- ² Pediatric Intensive Care Unit, Hospital Infantil de Mexico Instituto Nacional de Salud, Mexico 15
- City, Mexico³ Infectious Diseases Department, Hospital Infantil de Mexico Federico Gomez Instituto 16 Nacional de Salud, Mexico City, Mexico. 17
- ³ Department of Infectious Diseases, Hospital Infantil de Mexico Federico Gomez Instituto Nacional 18
- 19 de Salud, Mexico City, Mexico.
- ⁴ Department of Pediatrics, Infectious Diseases Hospital, UMAR National Medical Center "La Raza", 20
- Instituto Mexicano del Seguro Social, Ciudad de Mexico, Mexico 21
- 22 ⁵ Ambulatory Pediatrics, Hospital Infantil de Mexico Federico Gomez Instituto Nacional de Salud
- Instituto Nacional de Salud, Mexico City, Mexico. 23
- ⁶Respiratory Medicine Department, Hospital Infantil de Mexico Federico Gomez Instituto Nacional 24
- 25 de Salud, Mexico City, Mexico.
- ⁷ Cardiology Department, Hospital Infantil de Mexico Federico Gomez Instituto Nacional de Salud, 26
- 27 Mexico City, Mexico
- ⁸ Department of Clinical Research, Hospital Infantil de Mexico Federico Gomez Instituto Nacional de 28
- Salud, Mexico City, Mexico 29
- ⁹ Research Division, Hospital Infantil de Mexico Federico Gomez Instituto Nacional de Salud, 30
- Mexico City, Mexco 31
- ¹⁰ Hospital Infantil de Mexcio Federico Gomez Instituto Nacional de Salud, Mexico City, Mexico 32
- 11 Neruosciences Research Laboratory, Hospital Infantil de Mexico Federico Gomez Instituto 33
- Nacional de Salud, Mexico City, Mexico 34
- ¹² Research Division, Hospital Infantil de Mexico Federico Gomez Instituto Nacional de Salud. 35
- Mexico City, Mexico 36
- 37

38 * Correspondence:

- Maria F. Castilla-Peon fernandacastillapeon@gmail.com 39
- Nadia Gonzalez-García nadia.him@gmail.com 40
- 41

It is made available under a CC-BY-NC-ND 4.0 Internationa Piters outcomes in Mexico City

42 Abstract

- 43 Background: pediatric inflammatory multisystem syndrome (PIMS) is a complication of severe acute
- 44 respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children that resembles Kawasaki
- 45 syndrome and poses children at high risk of cardiorespiratory instability and/or cardiac damage. This
- 46 study aims to describe the clinical presentation and outcomes of patients with PIMS in Mexico City.
- 47 Methods: this was an observational study (May 1, 2020, to September 30, 2021) of children with
- 48 PIMS according to Centers of Disease Control and Prevention case definition criteria, hospitalized in

49 a single tertiary care pediatric center in Mexico City. Demographic characteristics, epidemiological

- 50 data, medical history, laboratory tests, cardiology evaluations, treatment, and clinical outcomes were
- 51 analyzed.
- 52 Results: Seventy-five cases fulfilled case-definition criteria for PIMS (median age 10.9 years, IQR:
- 53 5.6-15.6). Fifteen (20%) had a severe underlying disease. Forty-eight cases (64%) were admitted to
- the intensive care unit, 33 (44%) patients required invasive mechanical ventilation, and 39 (52%)
- 55 received vasopressor support. Two distinct groups of patients were identified: cluster 1 (n=60) who
- 56 had rash or gastrointestinal symptoms and cluster 2 (n=15) with predominantly respiratory
- 57 manifestations. Two cases (2.7%) died, both with severe underlying conditions. Five cases (6.7%)
- 58 developed coronary aneurysms, all of them from cluster 1.
- 59 Conclusion: clinical manifestations and outcomes are in general comparable what has been
- 60 previously reported in international series. In our series, there was a high proportion of patients with
- 61 severe respiratory involvement and positive RT-PCR SARS-CoV-2 and a low frequency of coronary
- aneurysms which suggests a possible higher proportion of children with severe acute COVID-19 in
- 63 our included cases.

64 Keywords: pediatric multisystem inflammatory disease, COVID-19, SARS-CoV-2, children,

- 65 coronary aneurysms, Mexico.
- 66

67 Introduction

- 68 Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) usually has a mild
- 69 clinical presentation in children. However, in rare cases, children can be severely affected and have
- clinical manifestations different from adults. In April 2020, some reports described a clinical
- 71 syndrome similar to Kawasaki disease or toxic shock syndrome temporally associated with current or
- 72 recent SARS-CoV-2 infection in the pediatric population(1). Since then, this syndrome has been
- recognized worldwide and named pediatric inflammatory multisystem syndrome (PIMS) or
- 74 multisystem inflammatory syndrome in children (MIS-C). (2–6).
- 75 PIMS case definition varies slightly between different health agencies (7–9) and is likely to change
- 76 over time. Criteria include fever, inflammatory marker elevation, multisystem organ involvement,
- 77 evidence of current or recent SARS-CoV-2 infection, and exclusion of alternative diagnoses. Besides
- the need for hospitalization for life support, an outcome of concern is possible myocardial and
- 79 coronary artery involvement similar to those observed in Kawasaki disease (10–12).

- PIMS incidence has been estimated to be approximately 3-5 per 10,000 individuals younger than 21
 years of age infected with SARS-CoV-2. Black and Hispanic ethnicities have been associated with a
- 81 years of age infected with SA82 higher incidence (13).
- 83 Epidemiological description of PIMS has been difficult because of varying awareness of the
- 84 condition in different clinical scenarios and because of the diversity of clinical manifestations.
- 85 Besides, there is an overlap between the clinical manifestations of severe acute COVID-19 and PIMS
- 86 (10). Current PIMS case definition is purposely broad and unspecific in the aim to collect the
- 87 maximum information about this phenomenon. However, increasing evidence suggests the existence
- 88 of different phenotypes of PIMS, the more clearly defined of them being a Kawasaki-like syndrome,
- 89 a Toxic Shock-like syndrome, and a predominantly respiratory syndrome which might have different
- 90 pathogenesis and clinical outcomes. (14–16).
- 91 This study aims to describe the clinical characteristics and outcomes of PIMS cases admitted to a
- 92 tertiary care pediatric center in Mexico City. An attempt was made to define different subgroups of
- 93 patients who otherwise fulfilled case definition criteria for PIMS.

94 Methods

- 95 *Study design*. This is a cross-sectional analysis of PIMS cases diagnosed in "Hospital Infantil de
- 96 México Federico Gómez" (Federico Gómez Mexico Children's Hospital), a tertiary care pediatric
- 97 facility officially designated to attend patients with severe SARS-CoV-2 infection in the population
- 98 younger than 18 without public or private health insurance in Mexico City.
- 99 Possible PIMS cases were identified in the emergency room, were transferred from other health care
- 100 facilities directly to the Intensive Care Unit or were identified by treating physicians in the general
- 101 hospitalization ward for COVID-19 patients. Cases were evaluated to determine if they met the CDC
- 102 PIMS case definition(7). In brief, criteria included the presence of fever, the elevation of
- 103 inflammatory markers, signs of involvement of at least two organic systems requiring hospitalization,
- and evidence of recent SARS-CoV-2 exposure or infection. Patients were excluded if they had
- another plausible explanation for the illness. When there was uncertainty about an alternative
- 106 diagnosis, the complete case file was reviewed by an expert panel which included an infectious
- 107 disease and a critical care specialist, and a consensus was reached. Detailed inclusion criteria are
- 108 specified in Chart 1.
- 109 Data collection. Clinical and laboratory data were extracted from the clinical file and included
- 110 demographics, underlying medical conditions, clinical manifestations, laboratory values,
- 111 management, and outcomes. For laboratory values with more than one measurement, the worst value
- measured within the first three days of hospitalization was registered. Vital support management
- 113 (respiratory support and vasopressor utilization), intravenous immune globulin, systemic steroids,
- and anticoagulant therapy were documented as the main therapeutic interventions. Outcomes of
- 115 interest were intensive care unit (ICU) admission, length of ICU and hospitalization stay, need for
- 116 invasive mechanical ventilation, vasopressor support, myocardial depression (left ventricular ejection
- 117 fraction < 55%), coronary aneurysms (coronary artery diameter z-score >= 2.5), or dilatation (z-score
- $118 \qquad 2 > < 2.5$) on the echocardiographic evaluation performed during hospitalization, and in-hospital
- 119 mortality. Markers with more than 20% missing data were not analyzed.
- For this study, severe respiratory involvement was defined as infiltrates on chest X-ray or computed tomography plus the need for oxygen administration with a non-re-breathable mask or a higher

- 122 oxygen concentration device. The variable "gastrointestinal symptoms" was defined as the presence
- 123 of at least one of the following: abdominal pain, diarrhea or emesis.
- 124 The study center has an important population of patients with severe underlying diseases. To have a
- 125 picture more alike general population, we performed a sub-analysis with the exclusion of cases with
- 126 severe underlying diseases (i.e., cancer and other forms of immunosuppression, neuromuscular
- disability, chronic respiratory disease except for asthma, congenital cardiopathies, and chronic kidney
- 128 failure).
- 129 Statistical analysis. Descriptive analysis was undertaken in STATAv.14.0 (StataCorp, Tx).
- 130 Categorical variables are reported as frequencies and continuous variables as medians and
- 131 interquartile ranges (IQR). Analysis was performed in the whole sample and three subgroups. In the
- 132 first subgroup, cases with severe underlying conditions were excluded. The other two groups were
- 133 derived using latent class analysis (LCA). Two class LCA were conducted using the R software
- 134 package "poLCA" (17) with 100 iterations to identify the clusters. The indicator variables used in
- 135 LCA were the presence or absence of severe respiratory involvement, rash, and gastrointestinal
- 136 symptoms. The fit of each model was assessed using a Bayesian Information Criterion score.
- 137 The ethics review board of Federico Gómez Mexico Children's Hospital authorized the analysis and
- 138 publication of de-identified data (Reg: HIM2020-031).

139 **Results**

- 140 Clinical departments sent 167 reports of cases with probable PIMS admitted to the Hospital from
- 141 May 1, 2020, through September 30, 2021. For reference, during this period, 8193 real time
- 142 polymerase chain reaction (RT-PCR) tests for SARS-CoV-2 tests were performed in the study center,
- 143 from which 837 had a positive result.
- 144 From the 167 received reports, 42 were from the emergency department, 34 from the intensive care
- unit, and 91 from the infectious disease department. Duplicated reports were eliminated (n=23), 23
- reports failed to meet inclusion criteria and 46 were excluded because an alternative etiology was
- 147 found to explain the clinical manifestations after the comprehensive review of the case's file and
- 148 consensus among researchers. All subsequent analyses were performed in the remaining 75 cases
- 149 unless otherwise specified.
- 150 The median (interquartile range, IQR) age was 10.9 (5.6-15.6) years old and 52% were female. At
- 151 least one underlying condition was found in 45.3% of the population, including obesity (25%),
- 152 cancer (9%), neuromuscular (8%), and respiratory (7%) diseases among others (Table 1).
- 153 In addition to fever, the most common clinical manifestations were cough (52%), conjunctivitis
- 154 (50.6%), abdominal pain (51%), rash (48%), headache (45.3%), and diarrhea (44%). The median
- 155 (IQR) duration of symptoms before admission was 7 (4-9) days. About 51% had lower respiratory
- symptoms, 85% had pulmonary infiltrates in the radiograph or computed tomography, and 65.3%
- required oxygen administration with a non-rebreathable mask, high flow nasal cannula, or
- mechanical ventilation. Vasopressor support was used in 52% of cases, and about 40% had a left
- ventricular ejection fraction < 55% on echocardiography. Median values for markers of
- 160 inflammation, coagulation, and system damage are summarized in table 1.

- 161 Three subgroups were analyzed independently. In the first subgroup (n=60), 15 cases with a severe
- 162 underlying disease were excluded. Clinical manifestations and outcomes did not differ significantly 163 from those observed in the total sample (Table 1 and 2)
- 163 from those observed in the total sample (Table 1 and 2)
- 164 The second (n=60) and third (n=15) subgroups were derived from LCA which identified two classes
- 165 of patients: cluster 1 (n=60) composed of patients with rash and/or gastrointestinal symptoms, and
- 166 cluster 2 (n=15) with predominant cardiorespiratory involvement without a rash or gastrointestinal
- symptoms. Despite the reduced number of cases in cluster 2, some differences are evident: cluster 2
- 168 cases were more prone to have a positive RT-PCR test (76% vs 100%, p=0.04) and less so to have a
- 169 positive serology test (0 vs 54%, p<0.001). An underlying medical condition was also more frequent
- in cluster 2 (80 vs 36.7%, p=0.003), especially a severe one (47 vs 13%, p=0.008) such as cancer,
- 171 neuromuscular disability, or a chronic respiratory condition. (Table 1). Cluster 1 patients tended to
- have higher levels of inflammation markers, though the difference was statistically significant only
- 173 for the neutrophil count and D-Dimer concentration.
- About treatment, 45.3%, 64%, and 63% of cases received intravenous immune globulin, systemic
- steroids, and anticoagulation therapy respectively, much more frequently in the cluster 1 group.
- 176 (Table 2)
- 177 Regarding outcomes, two (2.7%) patients died. Both had severe underlying diseases; the first one had
- a medulloblastoma and died two weeks after the antineoplastic chemotherapy dose and the second
- 179 one had chronic kidney failure and was on dialytic replacement therapy. One death occurred in each
- 180 cluster group. About 44% of cases needed mechanical ventilation, 52% of cases required vasopressor
- 181 support while 40% had a depressed ventricular function. (Table 2)
- 182 All cases had an echocardiographic evaluation during hospitalization. Five cases (6.7%) had coronary
- aneurysms. Notably, all cases with aneurysms were in Cluster 1. No patient had a coronary diameter
- 184 with a z-score between 2.0 and 2.5. Myocardial involvement (left ventricular ejection fraction <
- 185 55%) was observed in 30(40%) of cases. Intensive care unit (ICU) admission occurred in 64% of
- 186 cases with a median (IQR) length of stay there of 5 (3-8) days and a length of hospital stay of 7(4-
- 187 13). There was a tendency of cluster 2 patients to remain longer in ICU and in hospital. (Table 2)

188 **Discussion**

- 189 The present study describes the largest cohort of patients with PIMS in the Mexican population to
- 190 date, as long as we are aware. Most clinical characteristics and outcomes of our series were like those
- described in large international reports. The median age of our sample was some years older than
- 192 most series. Prevalence of underlying medical conditions, including obesity was similar to the
- reported in the United States and Latin America (10,16,18–20), except for cancer which is relatively
- 194 frequent in our total sample, reflecting the characteristics of the population regularly attending the
- 195 study center. Cardiac dysfunction, vasopressor requirements, rash, and gastrointestinal symptoms
- 196 were comparable to those reported elsewhere, so as ICU admissions, length of hospital stay, and
- length of ICU stay. The death rate of 2.7% (binomial 95% confidence interval: 0.3-9.3%) was similar
- 198 to the previously reported (3,5,10,14,18,21).
- 199 Our population had a relatively high frequency of lower and serious respiratory involvement in
- 200 comparison with most of the other series. Besides, in our sample, serology was performed in only 201 55% of cases, so the evidence of SARS-CoV-2 infection in our population is mostly by RT-PCR
- 201 3370 of cases, so the evidence of SARS-Cov-2 infection in our population is mostly by R1-PCR 202 (80% positivity rate). These findings might point toward a higher proportion of acute severe SARS-
- 203 CoV-2 infection vs a theoretical late-onset post-infectious syndrome in our sample compared to

204 other case series where respiratory involvement and RT-PCR positive rate was lower (3,5,10,14,18).

205 Current PIMS diagnostic criteria does not exclude acute severe COVID-19; this overlap between

206 both clinical presentations has been previously discussed (10,16).

207 On the other hand, the frequency of coronary aneurysms in our study was relatively low (6.7%).

- Aneurysm frequency is heterogeneous among reports, varying from 6.7 to 23.3% (14,18,19,21). This
- 209 probably reflects the lack of specificity on the PIMS case-definition criteria and the variability of the
- 210 cut-point for some inflammatory markers used in different reports. Most case series are derived from
- 211 active or passive surveillance, either retrospectively or prospectively. Many of them do not inform a
- 212 cut-point for inflammatory markers concentration, or clinical symptoms and it is assumed that the
- higher limit of the normal reference range was used. This probably explains the high frequency of
- coronary aneurysms (23.3%) found by Flood et al., in the United Kingdom, their study having a very high cut-point for CRP (100mg/L) and requiring "acute abdomen" and very specific dermatological
- high cut-point for CRP (100mg/L) and requiring "acute abdomen" and very specific dermatological
 findings, not only "abdominal pain" or "rash" as criteria for gastrointestinal or mucocutaneous
- 217 involvement respectively (14). Stringency in diagnostic criteria automatically excludes a high
- 218 proportion of potential cases keeping a more homogeneous and severely affected population.
- 219 Notably, none of the five aneurysm cases of our series had a serious underlying disease and all of
- them belonged to cluster 1 (Mucocutaneous/gastrointestinal predominant symptoms). Although ours
- was a small sample to make any inference, it supports the increasing awareness about the existence of
- different clinical phenotypes. Godfred-Cato et al.(15), and later Geva et. al(16), identified three
- classes of patients: 1) a seriously ill group with significant cardiovascular involvement, multiple
- organ dysfunction, a pronounced elevation of inflammatory markers who tended to have positive
- serology for SARS-CoV-2, a second group with predominant respiratory involvement and high RT-
- PCR positivity rate that resembles our cluster 2 group, and the third group with predominant
- Kawasaki- like mucocutaneous findings. Meanwhile, Flood et al. also identified three PIMS
 phenotypes using cluster analysis: PIMS with Kawasaki disease-like presentation. PIMS with
- findings of Kawasaki disease and shock, and PIMS without any of these features (14) and consensus
- derived clinical recommendations have been generated accordingly (22). In all three cluster
- analyses, coronary artery aneurysms are more frequent in groups with Kawasaki-like features and
- higher levels of inflammatory markers, which in our cluster analysis corresponds to Cluster 1. It
- might be important to differentiate the clinical subtypes diagnosed as PIMS under the umbrella of
- CDC and WHO case definition criteria, since probably not all of them benefit from the same
- therapeutic interventions. The role of inflammation along all spectrum of severe illness associated
- with SARS-CoV-2 infection should be deeply studied, including its role in myocardial disfunction
- since it is a frequent complication both in adults with COVID-19 and children with PIMS. (23)
- A limitation of this study, as in others, is the method for identification of included cases for analysis
- 239 depending on spontaneous reports by treating clinicians. In the future, a prospective multicentric
- 240 cohort design with clear-cut criteria for subclassification of every patient fulfilling the broad clinical
- criteria after SARS-CoV-2 infection would provide more information on the outcomes and possible
- associated factors.

243 Conclusions

- 244 Epidemiology of PIMS cases observed in our center is comparable to the reported elsewhere,
- although our series included a high proportion of patients with an acute-like respiratory phenotype.
- 246 Coronary aneurysms are infrequent and usually present in previously healthy patients with rash or

- 247 gastrointestinal symptoms. The death rate is alike the reported elsewhere and occurred in patients
- 248 with severe underlying diseases.
- 249 We agree with other researchers that underneath the umbrella of case definition for criteria for
- 250 COVID-19 at least two groups of patients can be identified according to their clinical presentation.
- 251 Standardized criteria for sub-classification of PIMS cases need to be developed, since different
- 252 phenotypes might have different pathophysiology, different outcomes, and possibly require different
- 253 management. Clinical trials are needed to evaluate therapeutic interventions in different PIMS
- 254 phenotypes.

255 **Conflict of Interest**

- The authors declare that the research was conducted in the absence of any commercial or financial
- 257 relationships that could be construed as a potential conflict of interest.

258 Data Availability

All data produced in the present study are available upon reasonable request to the authors

260 Author Contributions

- All authors contributed with study planning, design and review of the final manuscript. RGG,
- 262 MLMY, RNJJ, VBOL contributed with data collection . HMG coordinated the research team. MFCP
- and NGG performed data analysis and the writing of the manuscript.

264 Funding

265 This study was funded by Hospital Infantil de México Federico Gómez

266 Data Availability Statement

- 267 The datasets generated for this study can be requested to corresponding authors.
- Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory
 shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607–8.
- Cheung EW, Zachariah P, Gorelik M, Boneparth A, Kernie SG, Orange JS, et al. Multisystem
 Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and
 Adolescents in New York City. JAMA J Am Med Assoc. 2020;324(3):294–6.
- Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, et al. Clinical
 Characteristics of 58 Children with a Pediatric Inflammatory Multisystem Syndrome
 Temporally Associated with SARS-CoV-2. JAMA J Am Med Assoc. 2020;324(3):259–69.
- Licciardi F, Pruccoli G, Denina M, Parodi E, Taglietto M. SARS-CoV-2 Induced KawasakiLike Hyperin fl ammatory Syndrome□: A Novel COVID Phenotype in Children. Pediatrics.
 2021;146(2):1–5.
- 5. Dufort EM, Koumans EH, Chow EJ, Rosenthal EM, Muse A, Rowlands J, et al. Multisystem
 Inflammatory Syndrome in Children in New York State. N Engl J Med. 2020;383(4):347–58.

281 6. Assessment RR. European Centre for Disease Prevention and Control Country Experts. Rapid 282 Risk Assessment: Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection 283 in children. https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-risk-284 assessment. 2020;(May):1–18. 285 7. HAN Archive - 00432 | Health Alert Network (HAN) [Internet]. [cited 2021 Dec 14]. 286 Available from: https://emergency.cdc.gov/han/2020/han00432.asp 287 8. Royal College of Paediatrics and Child Health. Guidance paediatric multisystem inflammatory 288 syndrome temporally associated with Cov-19. R Coll Paediatr Child Heal. 2020;1-6. 289 9. Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem 290 inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020;20(11):e276-88. 291 10. Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, et al. 292 Characteristics and Outcomes of US Children and Adolescents with Multisystem 293 Inflammatory Syndrome in Children (MIS-C) Compared with Severe Acute COVID-19. 294 JAMA - J Am Med Assoc. 2021;325(11):1074-87. 295 11. Son MBF, Murray N, Friedman K, Young CC, Newhams MM, Feldstein LR, et al. 296 Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes. N Engl J 297 Med. 2021;385(1):23-34. 298 12. Davies P, Evans C, Kanthimathinathan HK, Lillie J, Brierley J, Waters G, et al. Intensive care 299 admissions of children with paediatric inflammatory multisystem syndrome temporally 300 associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. Lancet 301 Child Adolesc Heal. 2020;4(9):669–77. 302 13. Payne AB, Gilani Z, Godfred-Cato S, Belay ED, Feldstein LR, Patel MM, et al. Incidence of 303 Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-304 CoV-2. JAMA Netw Open [Internet]. 2021 Jun 1 [cited 2021 Dec 14];4(6):e2116420-305 e2116420. Available from: 306 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2780861 307 14. Flood J, Shingleton J, Bennett E, Walker B, Amin-Chowdhury Z, Oligbu G, et al. Paediatric 308 multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS): 309 Prospective, national surveillance, United Kingdom and Ireland, 2020. Lancet Reg Heal - Eur 310 [Internet]. 2021 Apr 1 [cited 2021 Dec 14];3. Available from: 311 http://www.thelancet.com/article/S2666776221000521/fulltext 312 15. Godfred-Cato S, Bryant B, Leung J, Oster ME, Conklin L, Abrams J, et al. COVID-19-313 Associated Multisystem Inflammatory Syndrome in Children - United States, March-July 314 2020. MMWR Morb Mortal Wkly Rep [Internet]. 2020 Aug 14 [cited 2021 Dec 315 14];69(32):1074–80. Available from: https://pubmed.ncbi.nlm.nih.gov/32790663/ 316 16. Geva A, Patel MM, Newhams MM, Young CC, Son MBF, Kong M, et al. Data-driven 317 clustering identifies features distinguishing multisystem inflammatory syndrome from acute 318 COVID-19 in children and adolescents. EClinicalMedicine [Internet]. 2021;40:09–10. 319 Available from: https://doi.org/10.1016/j.eclinm.2021.101112

- Linzer DA, Lewis JB. poLCA: An R package for polytomous variable latent class analysis. J
 Stat Softw. 2011;42(10):1–29.
- Belay ED, Abrams J, Oster ME, Giovanni J, Pierce T, Meng L, et al. Trends in Geographic
 and Temporal Distribution of US Children with Multisystem Inflammatory Syndrome during
 the COVID-19 Pandemic. JAMA Pediatr. 2021;175(8):837–45.
- States U, July M, Godfred-cato S, Bryant B, Leung J, Oster ME, et al. COVID-19–Related
 Multisystem Inflammatory Syndrome in Children. AAP Gd Rounds. 2020;44(3):30–30.
- 327 20. Torres JP, Izquierdo G, Acuña M, Pavez D, Reyes F. Multisystem inflammatory syndrome in 328 children (MIS-C): Report of the clinical and epidemiological characteristics of cases in 329 Santiago de Chile during the SARS-CoV-2 pandemic Juan. Int J Infect Dis. 330 2020;2020(100):75–81.
- Antúnez-Montes OY, Escamilla MI, Figueroa-Uribe AF, Arteaga-Menchaca E, LavariegaSaráchaga M, Salcedo-Lozada P, et al. COVID-19 and Multisystem Inflammatory Syndrome
 in Latin American Children: A Multinational Study. Pediatr Infect Dis J. 2020;40(1):1–6.
- Harwood R, Allin B, Jones CE, Whittaker E, Ramnarayan P, Ramanan A V., et al. A national
 consensus management pathway for paediatric inflammatory multisystem syndrome
 temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. Lancet
 Child Adolesc Heal. 2021;5(2):133–41.
- Eiros R, Barreiro-Pérez M, Martín-García A, Almeida J, Villacorta E, Pérez-Pons A, et al.
 Pericardial and myocardial involvement after SARS-CoV-2 infection: a cross-sectional
 descriptive study in healthcare workers. Rev Española Cardiol (English Ed. 2021;

341

It is made available under a CC-BY-NC-ND 4.0 International license .

Chart 1. Case definition criteria for PIMS									
1.	Fever								
2.	Elevation of inflammation markers	At least one of the following: • C-Reactive Protein (CRP) >5mg/L • Procalcitonin > 0.15 ng/ml • Ferritin > 300 mcg/L • Fibrinogen > 400 mg/dl • D-Dimer >560 ng/ml • Neutrophils > 7500 cells/mcl • Lymphopenia: <2 years: <4000, 2-3 years: < 3000, >4 years: <1500 cells/mcl							
3.	At least two systems involved	 Albumin < 3 g/dl 3.1 Cardiovascular. At least one of the following: Required vasoactive drug Left ventricular ejection fraction < 55% 3.2 Respiratory. At least one of the following: Supplementary oxygen with non-rebreathable mask or higher oxygen concentration device. Oxygen saturation <90% Pulmonary infiltrates in chest X-Ray or Computed Tomography 3.3 Neurologic. At least one of the following: Glasgow score < 14 if not sedated Meningismus Seizures 3.4 Hematologic. At least one of the following: Plateletes< 150 000 cells/mcl Prothrombin time >14 sec 3.5 Gastrointestinal. At least one of the following: Abdominal pain Vomit Diarrhea Alanineaminotransferase (ALT) > 90 U/L 3.6 Mucocuteneous. At least one of the following: Rash Extremity edema Desquamation Mucosal inflammation Conjuntivitis 							
		 Creatinine > twice upper limit of the reference range for age 							
4.	Hospitalization	** 0 0							
5.	No alternative diagnosis	 No positive blood culture during the first 48 hours in the hospital In uncertain cases, complete file review and consensus by an expert panel. 							
6.	Present or recent infection by SARS- COV2	 At least one of the following Positive RT-PCR¹ for SARS-COV2 Positive serology for SARS-COV2 Contact with a confirmed positive COVID-19 case in the last four weeks. chain reaction. 							

It is made available under a CC-BY-NC-ND 4.0 International license .

	Totalpopulation(N =75) ¹	Without serious underlying disease ² (N=60) ¹	Cluster 1 With GIS ³ or Rash (N=60) ¹	Cluster 2 Predominan respiratory (N=15) ¹
emale sex -no.(%)	39 (52%)	33(55%)	33 (55%)	6 (40%)
ge - median (IQR)	10.9 (5.6-15.6)	10.6 (5.5-15.0)	10.3 (5.7-13.5)	15.3 (5.4-16.6
ge group - n (%)				
<1 y	5 (6.7%)	5 (8.3%)	4(6.7%)	1 (6.7%)
1-4 y	11 (17.3%)	9 (15%)	9 (15%)	2 (1.3%)
5-9 y	13 (17.1%)	11 (18.3%)	12 (0.2%)	1 (6.7%)
10-14 y	26 (34.7%)	21 (35%)	23 (38.3%)	3 (20%)
15-18 y	20 (26.7%)	14 (23.3%)	12 (20%)	8 (53%)
ays of sympthoms before admission	7(4-9)	7 (5-9)	6 (4-8)	7 (1-9)
ARS-COV2 testing, No. (%)				
RT- PCR positive	57/71 (80%)	43/56(76.8%)	44/58 (75.9%)	13/13 (100%
Serology positive	25/41 (61%)	25/46 (54%)	25/46(54%)	0*
iderlying medical conditions - no. (%)				
Obesity (BMI > 95° percentile)	18 (24%)	14 (23.0%)	12 (20%)	6 (40%)
Respiratoriy	5 (6.7%)	3 (5%)	2 (3.3%)	3(20%)*
Nerumomuscular	6 (8.0%)	0	2 (3.3%)	4 (26.7%)*
Cardiovascular	3 (4%)	0	2 (3.3%)	1 (6.7%)
Cancer	7 (9.3%)	0	2 (3.3%)	5 (33%)*
Other, immunosupression	2 (3%)	0	1 (1.7%)	1 (6.7%)
Othercomorbidity	10 (13.3%)	6 (10%) ⁴	8 (13.3%)	2 (13.3%)
At least 1 underlyingcondition	34 (45.3%)	19 (31.2%)	22 (36.7%)	12 (80%)*
inicalmanifestations – no.(%)				
Cough	39(52%)	32 (53.3%)	33 (55%)	6 (40%)
Rash	36 (48%)	33 (55%)	36 (60%)	0
Conjuntivitis	39 (50.6 %)	39 (52%)	37 (61.7%)	2 (13.3%)
Diarrhea	33 (44%)	27 (45%)	33 (55%)	0
Abdominal pain	38 (51%)	36 (60%)	38 (63.3%)	0
Headache	34(45.3%)	25 (41.7%)	27 (45%)	7 (46.7%)
Rinorrhea	24 (32%)	20 (33.3%)	19 (31.7%)	5 (33.2%)
ResiratoryDistress	31 (41%)	24 (40%)	21 (35%)	10 (66.7%) ³
Lower respiratorysimptoms	41 (54%)	31 (51.7%)	29 (48.3%)	12 (80%)*
Anosmia/Dysgeusia	7 (9.3%)	6 (10%)	4 (6.6%)	3 (20%)
Arthralgias/Myalgias	14(18.7%)	11 (18.3%)	13 (21.7%)	1 (6.7%)
OxygenSaturation<90%	30 (40%)	20 (33.3%)	22 (36.7%)	8 (53.3%)
Laboratory v	alues within 72 h of admi	ssion – median (IQR)	/ n.(%)	
Neutrophil count x10° cells/mcl	6.1 (1.7-9.2)	7.1(3.1-10.1)	6-5 (1.9-9.8)	3.1(0.5-7.1)
Neutrofilia (>7500 cels/mm ²)	29/74 (39.2 %)	27/59 (45.8%)	27/59 (45.8%)	2 (13.3%)*
Neutropenia (<1000 ceks/mm ³)	10 (13%)	6 (10%)	5 (8.3%)	5 (33%)*
Lymphocyte count x10° cells/mm'	1.5 (0.5-2.4)	1.6 (0.8-2.1)	1.6 (0.6-2.8)	0.8 (0.4-1.8
Lymphopenia	43/73 (58.9 %)	33/58 (56.9%)	33/58 (56.9%)	10 (66.7%)
Plateletsx 10 [°] cells/mm [°]	162 (94-250)	166(110-271)	162 (105-235)	162 (43-330
Fibrinogen, mg/dl	510 (404-668)	558(431-724)	516 (412-671)	510 (361-669
Fibrinogen> 400 mg/dl	52 (69.3%)	44/56 (78.6%)	43 (71.7%)	9 (60%)
Ferritinmcg/L	617 (407-1370)	559 (380-1110)	604 (417-1150)	1370 (325-607
Ferritin> 300 mg/dl	53 (70.1%)	41 (68.3%)	46/55 (83.6%)	7/9 (77.7%)
D-Dimer ng/L	2.6 (1.1-6.5)	2.9(1.2-8.8)	3.5(1.3-9.5)	0.8 (0.5-1.2)
D- Dimer> 560ng/ml (0.56 ng/L)	66/74 (89.2%)	55 (91.7%)	55/59 (93%)	11/15 (73.3%
C-reactive protein (mg/L)	9.8 (4.5-18.9)	13.5 (6.1-19.9)	13.2 (5.9-19.1)	7.3 (0.7-17.7
C-reactive protein > 5mg/L	47/63 (74.6%)	41/50 (82%)	42/54 (77.8%)	5/9 (55.5%)
Procalcitonin ng/ml	1.85 (0.5-6.3)	1.8(0.47-3.84)	2.1 (1.16-6.4)	0.37 (0.12-6.1
Procalcitonin > 0.15 ng/ml	55/62 (88.7%)	43/50 (86%)	47/51 (92%)	8/11 (72.7%
Albumin< 3g/dl	45/71 (63.3%)	36/56 (64.3%)	40/57 (70.2%)	5/14 (35.7%)

reported in each cell.²Excluded: cancerl, immunodefiicency, neuromuscular, chronic respiratory disease except asthma, congenital cardiopathies, chronic kidney failure.³GIS: Gastrointestinal sympthoms, includes abdominal pain, diarrhea, emesis.⁴Trisomy 21 (n=1), Post recent appendicectomy (n=2), hypothyroidism (n=2), undernutrition (n=1).⁵Lymphopenia: (<2 years: <4000, 2-3 years: <3000, >4 years: <1500 cells/mcl)

*P<0.05, one-sided Fisher exact test/ Mann-Whitney test for comparison between cluster 1 and cluster 2.

It is made available under a CC-BY-NC-ND 4.0 International license .

Table 2. Treatment and outcomes of cases with PIMS											
	Total sample(N=75) ¹	Without serious underlying disease (N=60) ¹	Cluster 1 With GIS or rash (N=60) ¹	Cluster 2 Predominant respiratory (N=15) ¹	<i>p</i> *						
Treatment – no. (%)											
Intravenous immune globulin	34(45.3%)	32(53.3%)	33 (55%)	1 (6.7%)*	0.01						
Systemic steroids	48 (64.0%)	43 (71.7%)	44 (73.3%)	4 (26.7%)*	0.001						
Anticoagulation therapy	47 (62.7%)	40 (66.7%)	41 (68%)	6 (40%)*	0.04						
Maximum ventilatory support needed - no	o (%)										
Non-rebreather mask	8 (10.7%)	7 (11.7%)	1 (1.7%)	1 (6.7%)							
High flow nasal cannula	4 (5.3%)	2 (3.3%)	2 (3.3%)	2 (13.3%)							
Non-invasive mechanical ventilation	4 (5.3%)	4 (6.7%)	4 (6.7%)	0							
Invasive mechanical ventilation	33(44%)	25 (41.7%)	25 (41.7%)	9 (60%)	0.16						
Any infiltrates in chest Rx or CT	60/71 (85%)	48/56 (85.7%)	45/56 (80%)	15 (100%)	0.06						
Severe respiratory involvment ²	28 (37.3%)	21 (35%)	19 (31.7%)	9 (60%)	0.04						
Cardiovascular involvement – no $(\%)$	(e e)	(,		2 (00,0)							
LVEF ³ <55%	30 (40.0%)	24 (40%)	22 (36.7%)	8 (53.3%)	0.18						
LVEF<45%	6 (8.0%)	5 (8.3%)	6 (10%)	0	0.25						
LVEF <35%	0	0	0	0	0.20						
Coronary aneurysm (z score $>$	5 (6.7%)	5(8.3%)	5 (8.3%)	0	0.32						
2.5)	- (
Coronary dilatation (z score >2 - <2.5)	0	0	0	0							
Vasopressor support – no (%)	39 (52.0%)	30 (50%)	32 (53.3%)	7 (46.7%)	0.43						
Hematologic involvement	50 (66.7%)	39 (65%)	39 (65%)	12 (80%)							
Thromboplastin time > 14 s	37/72 (51.5%)	30 (50%)		()	0.26						
Platelets count <150 000 cell/mcl	29 (38.7%)	21 (35%)	24 (40%)	6 (40%)	1.0						
Neurologic involvement ⁴	5 (6.7%)	5 (8.3%)	5 (8.3%)	0	0.32						
Gastrointestinal involvement	60 (80%)	51 (85%)	57 (95%)	3 (20%)	< 0.001						
AlanineAminotransferase (ALT)	21/72 (29.2%)	16/58 (27.6%)	17/58 (29.3%)	4/14(28.5%)	0.62						
> 90 U/L				<i></i>	0.001						
Mucocutaneous involvement	64 (85.3%)	39 (65%)	58 (96.7%)	6 (40%)	< 0.001						
Acute Kidney Injury, stage 2	19/74 (25.7%)	26.7%	19 (31.7%)	0	0.01						
Clinical outcomes- no.(%) / median (IQR)	AF (4 4 4 4 4	00 ((00))	10 / / / = + + +							
ICU [°] admission	48 (64%)	37 (61%)	38 (63%)	10 (66.7%)	0.53						
Length of ICU stay-d (n=48)	5 (3-8)	4(3-8)	4.5 (3-8.3)	1.5 (3.5-13.5)	0.23						
Length of Hospital stay days	7 (4-13)	7(4-11)	7 (4-12)	10 (5-17)	0.31						
Died	2 (2.7%)	0	1 (1.7%)	1 (6.7%)	0.36						

¹ N in the column heading was used to calculate proportions if not otherwise specified. For variables with missing data, denominators are reported in each cell.²Severe respiratory involvment was defined as oxygen requirement and infiltrates in thoracic imaging.³LVEF= Left ventricular ejection fraction.⁴ Neurologic involvment: seizures (n=3), optic neuritis (n=1), meningismus (n=1), headache not included. ⁵Acute Kidney Injury (AKI) was defined as an increase greater than two times the upper limit of the reference range for gender and age. ⁶ ICU: intensive care unit. * Comparison Cluster 1 vs. cluster 2 with Fisher exact test/ Mann-Whitney test